A detailed history of Gts Securities LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Gts Securities LLC holds 74,000 shares of BCRX stock, worth $575,720. This represents 0.0% of its overall portfolio holdings.

Number of Shares
74,000
Previous 13,800 436.23%
Holding current value
$575,720
Previous $85,000 561.18%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $239,279 - $393,392
57,937 Added 421.51%
71,682 $442,000
Q1 2024

May 15, 2024

SELL
$4.89 - $7.65 $99,110 - $155,050
-20,268 Reduced 59.59%
13,745 $69,000
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $54,660 - $74,307
10,976 Added 47.65%
34,013 $203,000
Q3 2023

Nov 15, 2023

BUY
$6.71 - $7.92 $31,785 - $37,517
4,737 Added 25.89%
23,037 $163,000
Q2 2023

Aug 15, 2023

BUY
$6.96 - $8.81 $127,368 - $161,223
18,300 New
18,300 $129 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.45B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.